US Bancorp
CCCC icon

US Bancorp’s C4 Therapeutics CCCC Stock Holding History

US Bancorp’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,000
Closed -$15.7K – 4054
2025
Q2 		$15.7K Sell
11,000
-600
-5% -$873 ﹤0.01% 3264
2025
Q1 		$18.6K Buy
11,600
+11,544
+20,614% +$34.4K ﹤0.01% 3201
2024
Q4 		$202 Buy
56
+18
+47% +$90 ﹤0.01% 4083
2024
Q3 		$217 Buy
+38
New +$229 ﹤0.01% 4009
2024
Q2 		– Sell
-39
Closed -$319 – 3994
2024
Q1 		$319 Buy
+39
New +$302 ﹤0.01% 3885
2022
Q2 		– Sell
-118
Closed -$3K – 4091
2022
Q1 		$3K Buy
+118
New +$2.87K ﹤0.01% 3722

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

US Bancorp's CCCC Position: Q3 2025 in Review

US Bancorp sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 11,000 shares — an estimated $15.7K sold.

US Bancorp first reported a position in CCCC in Q1 2022 and held it in 6 quarters. The position peaked at $18.6K in Q1 2025. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • US Bancorp reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • US Bancorp sold 11,000 C4 Therapeutics shares in Q3 2025, an estimated $15.7K.
  • US Bancorp first reported a position in C4 Therapeutics in Q1 2022 and held it in 6 quarters.
  • US Bancorp's C4 Therapeutics position peaked at $18.6K in Q1 2025.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on US Bancorp's 13F filing for Q3 2025, filed 12 Nov 2025.